Royalty Pharma plc Q3 2026 Earnings Recap

Royalty Pharma’s third-quarter results were broadly steady, with the stock up 1.7% after earnings. Receipts grew 9%, and the company raised 2026 guidance again, while the transcript also notes a disappointing Phase III outcome for pelacarsen.

Key Takeaways

• Third-quarter Portfolio Receipts and Royalty Receipts each grew 9%; Royalty Receipts were up 12% year to date.
• The company raised full-year 2026 guidance for the third consecutive quarter, citing business momentum.
• Royalty Pharma had deployed $1.6 billion of capital year to date and returned close to $590 million to shareholders through dividends and share repurchases in the first nine months.
• The company reported a 14.3% return on invested capital and a 20.2% return on invested equity.
• Pelacarsen’s Phase III results disappointed; management said the investment was structured to recover the capital invested plus a small return.